Biosign Signs Master Distribution Agreement With DLF Solutions Inc. for Exclusive Rights in the Canadian Market

Toronto, April 16, 2010 (ots/PRNewswire) - Biosign Technologies Inc.
(CNSX: BIO) ("Biosign" or the "Company"), and DLF Solutions Inc.
(DLF), today announced they have signed a binding Heads of Agreement
to enter into a Master Distribution Agreement to distribute Biosign
products in Canada through DLF Solutions Inc.

DLF Solutions Inc., a specialty logistic provider with supporting
establishment licenses, is positioned to leverage its extensive
relationship with key influencers within the healthcare industry to
introduce Biosign's revolutionary pulse-wave based diagnostic
products and services to multiple market segments in Canada.

"Establishing a strong foundation of business in our own backyard
is a critical step in the overall growth of Biosign, and we believe
that DLF, with their strong, Canadian-based healthcare experience, is
the right partner to lead these efforts." remarked Radu Leca,
President and CEO for Biosign.

Terms of the Master Distribution Agreement, include, among other
things, the following:

- DLF will agree to pay $500,000 CDN to BioSign through a combination of
license fee, and the purchase of UFIT units for use in pre marketing
activities and ongoing sales & marketing activities. The $500,000 will
be paid upon mutually agreed milestones;
- Minimum sales volume commitments over the term of the Agreement,
including a five (5) year growth plan achieving an expected $40M in
annual revenue;
- A transition of all existing resellers of Biosign products in Canada
to
DLF;
- Exclusivity of distribution in Canada to DLF for the Biosign product
portfolio for the duration of the Agreement.

"Biosign's novel approach to providing precise measurement and
rapid knowledge formation will have a material impact on the
healthcare and life sciences industries" said Mark Michalkoff,
President of DLF, "one of our professional program focuses is on the
evolving strategic shift in the pharmaceutical industry whereby
pharmacists will be instrumental in intervention, prevention and
counseling, and knowledgeable in the implementation and use of
pioneering technology for patient care."

About Biosign Technologies Inc.

Biosign provides biomedical systems. Key applications include
intelligent systems for noninvasive monitoring of common health risks
associated with blood pressure, glucose, and medication. The core
technology combines measurement, analysis, and rapid knowledge
formation to support health monitoring across global markets. The
UFIT(R) medical device technology powers quality data collection and
analytics for clinical diagnostics, self-care, wellness, disease
state evaluation & management, and remote patient monitoring. For
more information on Biosign please visit http://www.biosign.com

About DLF Solutions Inc.

DLF Solutions Inc. is a specialty logistics and program provider
to the pharmaceutical industry in Canada. DLF specializes in program
design, development, implementation and management support to a
number of multinational pharmaceutical companies in Canada, including
Triton Pharma Inc. and Ranbaxy Pharmaceuticals Canada Inc. DLF
recognizes and embraces the evolving strategic shift in the Canadian
pharmaceutical industry toward implementation of pioneering
technologies and is able leverage its extensive relationship base in
furtherance of these industry initiatives. For more information on
DLF please contact Mark Michalkoff at m.michalkoff@dlfsolutions.ca.

The CNSX has neither approved nor disapproved the contents of
this press release.

For further information: Radu Leca, President & CEO, Biosign
Technologies Inc., Phone: +1(416)218-9800 ext. 234, Email:
ceo@biosign.com

ots Originaltext: Biosign Technologies Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: For further information: Radu Leca, President & CEO,
BiosignTechnologies Inc., Phone: +1(416)218-9800 ext. 234, Email:
ceo@biosign.com